Bottleneck in SARS-CoV-2 vaccine production eliminated
Biotage is one of the few companies offering a complete solution and ready-to-go off-the-shelf products for the purification of large-scale lipids, used in mRNA vaccine development and production.
Expanding its production capacity of large-scale flash columns by 300%, Biotage is now helping pharmaceutical companies and contract manufacturers scale up lipid production for SARS-CoV-2 vaccines. A new, bespoke production facility is now operational at the Biotage site in Cardiff, UK.
The availability of raw materials for mRNA vaccine production has been a major bottleneck as the lipids that were needed for new lipid nano particle (LNP) formulations used in mRNA vaccines were not previously available on the scale needed to produce billions of doses of vaccine globally. The rapid development of a scalable and reliable route into commercial production of these lipids has been made possible with the aid of Biotage’s flash purification platforms, systems and expertise.
The newly opened production facility will enable Biotage to meet the increase in demand for this vital market segment, without any disruption to existing clients.